{"filings":[{"id":120776,"accession_number":"0001104659-25-118863","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Carisma voluntarily delisting from Nasdaq, terminating SEC reporting; appoints new CEO for wind-down","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved voluntary delisting from Nasdaq; Form 25 expected Dec 10; delisting effective 10 days later.","Company to file Form 15 to suspend and terminate SEC reporting obligations under Sections 13 and 15(d).","Steven Kelly appointed interim CEO (consulting) at $350/hour through Dec 31, 2025.","Craig Jalbert to become CEO, President, Treasurer, Secretary and director Jan 1, 2026; $50K/year via his firm.","Three directors and VP Finance McAndrew resigning effective Dec 31, 2025; no disagreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120775,"accession_number":"0001104659-25-099740","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Carisma Therapeutics terminates CEO (eff. Nov 15) and CSO; three directors resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Steven Kelly terminated without cause, effective Nov 15, 2025; gets $624K severance plus $299,948 prorated bonus and health payments.","CSO Michael Klichinsky terminated without cause, effective Oct 15, 2025; receives 12 months salary in installments, prorated bonus, $2,245/month health payment.","Directors John Hohneker, Briggs Morrison, David Scadden resigned Oct 15; Kelly resigns from board effective Nov 15.","Company will appoint a consultant as CEO to manage wind-down; prior retention bonus agreement with Kelly voided.","Wind-down of operations previously disclosed; no disagreement cited for director resignations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120774,"accession_number":"0001104659-25-098404","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Carisma Therapeutics to be delisted from Nasdaq on Oct 13; expects to wind down operations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq delisting letter; common stock suspended from trading effective Oct 13, 2025; no appeal planned.","Approval received to list common stock on OTCID market tier under symbol CARM starting Oct 13, 2025.","Company expects to pursue sale or monetization of remaining assets and orderly wind down of operations.","Warns that it is unlikely there will be meaningful cash available for distribution to stockholders.","May file Form 15 to suspend SEC reporting obligations after delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137363,"accession_number":"0001104659-25-091064","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","1.02","8.01"],"status":"ready","headline":"Carisma terminates merger with OrthoCellix, receives $4M from Moderna, expects wind-down","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Moderna pays $4M one-time to eliminate all future milestones, royalties, and research costs under the 2022 collaboration; licenses become fully paid-up and perpetual.","Merger with OrthoCellix/Ocugen terminated after OrthoCellix failed to secure $25M concurrent financing by Sept 15, 2025.","Carisma is owed $750K termination fee and $500K expense reimbursement from OrthoCellix; OrthoCellix has not confirmed payment; Carisma intends to enforce.","No meaningful cash expected for stockholders; company plans orderly wind-down or possible bankruptcy/liquidation absent a strategic transaction.","Nasdaq delisting risk by Oct 7, 2025; the Hearings Panel could delist earlier given the merger was central to compliance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137362,"accession_number":"0001104659-25-085705","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["1.01","3.02","5.01","5.02","8.01","9.01"],"status":"ready","headline":"Carisma enters $5M subscription deal with Ocugen; Nasdaq deadline extended to Oct 21","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Subscription agreement with Ocugen for $5M private placement as part of concurrent $25M financing.","CEO Steven Kelly amended employment agreement with retention/transaction bonuses contingent on merger closing.","Nasdaq extends bid price compliance deadline to Oct 21; must complete merger by Oct 7 and show $4 bid price.","Merger with OrthoCellix must close by Oct 7 for continued listing on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137361,"accession_number":"0001104659-25-075680","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Carisma stockholders approve reverse stock split at ratio of 1:10 to 1:50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders adopted reverse split amendment; board has sole discretion to set exact ratio (1:10 to 1:50) and timing.","Vote results: 21,783,014 for, 3,352,989 against, 92,853 abstain.","Adjournment proposal also approved but was not needed due to quorum and sufficient votes for the reverse split.","No further stockholder approval is required for implementation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137360,"accession_number":"0001104659-25-068098","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Carisma receives Nasdaq delisting notice for bid price non-compliance; schedules Aug 5 reverse split vote","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Carisma on July 9, 2025 that failure to regain bid price compliance is an additional delisting basis.","Listing transferred to Nasdaq Capital Market on June 12, 2025 with exception through Oct 7, 2025 to show compliance.","Special meeting set for Aug 5, 2025 to approve reverse stock split (1:10 to 1:50) to increase bid price.","No assurance reverse split will achieve compliance or Panel terms will be met by Oct 7, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154681,"accession_number":"0001104659-25-061397","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Carisma to merge with OrthoCellix; pre-merger holders to own ~10% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Carisma (CARM) enters merger with Ocugen subsidiary OrthoCellix; Merger Sub to merge into OrthoCellix, which becomes wholly owned subsidiary.","Pre-merger Carisma stockholders will own ~10% of combined company; Ocugen/OrthoCellix stockholders and Concurrent Investment investors will own ~90%, on fully-diluted basis.","Expected Concurrent Investment of at least $25M; Ocugen commits to purchase at least $5M of Carisma common stock at or immediately after closing.","Exchange ratio based on OrthoCellix valuation of $135M (less any shortfall in Concurrent Investment) and Carisma valuation of $15M (adjusted for net cash).","CVR Agreement grants pre-merger Carisma stockholders contingent cash payments from future disposition of legacy assets, including Moderna collaboration; no assurance of payment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154680,"accession_number":"0001104659-25-058622","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Carisma Therapeutics secures Nasdaq listing extension with transfer to Capital Market, strict conditions to Oct 7, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Panel granted exception; listing transferred to Nasdaq Capital Market effective June 12, 2025.","Must demonstrate closing bid price ≥$1.00 for 10 consecutive sessions by Oct 7, 2025.","Must complete a strategic transaction and meet all initial listing requirements for Capital Market by Oct 7.","Company had previously failed MVLS ($50M), MVPHS ($15M), and Bid Price ($1.00) rules.","Panel may reconsider if conditions not met; no assurance of compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154679,"accession_number":"0001104659-25-035517","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Carisma receives Nasdaq delisting notice for MVLS, MVPHS, bid price non-compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Carisma on April 10, 2025, of delisting for failing to maintain $50M MVLS by April 8, 2025 compliance deadline.","Company also failed $15M MVPHS rule; granted 180 days until October 7, 2025, to regain compliance.","Existing bid price non-compliance (below $1.00) has compliance period through July 7, 2025.","Carisma plans to request a hearing before Nasdaq Panel to stay delisting; no assurance of extension.","Company considering all options but cannot guarantee regaining compliance with any listing rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173204,"accession_number":"0001104659-25-002839","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Carisma updates pipeline: CT-1119 Phase 1 start H1 2025, liver fibrosis IND in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CT-1119 (mesothelin-targeted CAR-Monocyte) Phase 1 trial with tislelizumab in solid tumors expected to start H1 2025.","Phase 1 trial to enroll up to 12 patients in China; initial safety/efficacy data anticipated Q4 2025.","Liver fibrosis program: preclinical in 2025 to enable regulatory submission in 2026, followed by Phase 1 in 2026.","Corporate presentation updated on company website with these pipeline milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173203,"accession_number":"0001104659-25-002522","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Carisma Therapeutics receives Nasdaq bid price deficiency notice; has until July 7, 2025 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Jan 6, 2025 for non-compliance with minimum bid price of $1.00 per share.","Company has 180 days, until July 7, 2025, to regain compliance by having closing bid price ≥$1.00 for 10 consecutive business days.","If compliance not achieved, may transfer to Nasdaq Capital Market for additional 180-day period, subject to meeting other listing standards.","Company intends to monitor bid price and consider options including potential reverse stock split if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190229,"accession_number":"0001104659-24-131705","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Carisma Therapeutics appoints interim VP of Finance, principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Natalie McAndrew appointed interim VP of Finance effective Jan 1, 2025.","She will serve as principal financial officer and principal accounting officer.","Ms. McAndrew is a Senior Director at Danforth Advisors, providing finance and accounting services under a master services agreement.","Her background includes roles at Apertura Gene Therapy, Baudax Bio, Tmunity Therapeutics, Spark Therapeutics.","The services agreement with Danforth can be terminated by either party with 30 days cause or 60 days without cause."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190228,"accession_number":"0001104659-24-126550","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["2.05","5.02","8.01"],"status":"ready","headline":"Carisma Therapeutics reduces workforce by 34%, terminates CFO, discontinues lead candidate CT-0525","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction of 23 employees (34% of workforce); expects ~$2.7M in one-time termination costs, substantially complete by Q1 2025.","CFO Richard Morris terminated without cause effective Dec 31, 2024; entitled to 12 months base salary, target bonus, COBRA; retention option accelerated.","Discontinues lead product CT-0525 (HER2 solid tumor) due to competitive landscape; final patient already enrolled in Phase 1.","Revised plan focuses on in vivo mRNA/LNP CAR-M programs with Moderna, plus fibrosis, neurodegeneration, and other diseases; potential development of CT-1119.","Company expects to appoint a consultant as principal financial and accounting officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190227,"accession_number":"0001104659-24-115069","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Carisma Q3 net loss $12.7M; cash $26.9M; CT-0525 initial data expected Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.7M in Q3 2024 vs $21.4M in Q3 2023; R&D expenses fell to $11.3M from $19.6M.","Cash and equivalents $26.9M as of Sep 30, 2024, down from $40.4M at Jun 30; expected runway into Q3 2025.","Phase 1 CT-0525 (HER2 CAR-Monocyte) initial data for Cohorts 1 and 2 expected Q1 2025; protocol amended for repeat dosing with pembrolizumab.","Expanded Moderna collaboration to include two autoimmune targets; retains rights beyond those.","Liver fibrosis development candidate nomination expected Q1 2025; preclinical data to be presented at AASLD."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":16000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190226,"accession_number":"0001104659-24-112629","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Carisma Therapeutics announces director resignation and appointment of Sohanya Cheng","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Torok resigns from board effective Oct 31, 2024; cites other professional commitments, no disagreement.","Sohanya Cheng elected director effective Oct 31, 2024 as Class I director until 2027 annual meeting.","Cheng will serve on audit committee (Chair: Marella Thorell, Sanford Zweifach, Cheng).","Compensation: $40K annual cash retainer, plus committee fees, and option for 38,700 shares at Oct 31 closing price, vesting monthly over 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190225,"accession_number":"0001104659-24-108078","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Carisma Therapeutics receives Nasdaq deficiency notice for market value below $50M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Carisma on Oct 10, 2024 that MVLS fell below $50M minimum requirement.","Company has 180 days, until April 8, 2025, to regain compliance by closing at $50M+ for 10 consecutive days.","Failure to regain compliance may lead to delisting; company can appeal to a Nasdaq Hearing Panel.","Carisma will monitor MVLS and evaluate options to meet Nasdaq listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206731,"accession_number":"0001104659-24-087014","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Carisma Therapeutics Q2 2024 net loss $11.2M; CT-0525 data expected by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss improved to $11.2M in Q2 2024 from $19.9M in Q2 2023; R&D expenses declined to $15.3M.","Cash and equivalents $40.4M at June 30, 2024; expects to fund operations into Q3 2025.","Initial data from CT-0525 Phase 1 trial for HER2+ solid tumors expected by year-end 2024; FDA Fast Track granted.","Nominated first in vivo CAR-M development candidate targeting GPC3 under Moderna collaboration; $2.0M milestone received.","Liver fibrosis program development candidate nomination expected in Q1 2025; preclinical data at AASLD in Nov 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":12600000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206730,"accession_number":"0001104659-24-078451","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Carisma reports 75% ctDNA reduction in HER2 3+ patients in Phase 1 CT-0508 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["75% (6/8) evaluable HER2 3+ patients had ctDNA reduction (median 81%, range 33%-93%); no reduction in 5 HER2 2+ patients.","Best overall response: stable disease in 44% (4/9) of HER2 3+ patients; all HER2 2+ patients had progressive disease.","Phase 1 CT-0508 enrollment halted April 2024; all patient activities completed as of July 2024.","Company expects clinical data updates in Q3 2024 and initial Phase 1 data for follow-on CT-0525 in Q4 2024.","Preliminary data supports mechanism of action and potential for repeat dosing with CT-0525 in HER2 overexpressing cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206729,"accession_number":"0001104659-24-077372","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Carisma terminates Novartis manufacturing deal for CT-0508; pays $4M fee, suspends Phase 1 enrollment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Manufacturing and Supply Agreement with Novartis for CT-0508; effective July 31, 2024.","Will pay $4.0M termination fee to Novartis in Q3 2024, with potential credit if Substitute Product transferred by Dec 31, 2024.","Suspends enrollment of new patients in Phase 1 trial for CT-0508 to focus ex vivo oncology on follow-on candidate CT-0525.","Revised operating plan narrows pipeline, prioritizing CT-0525 over CT-0508."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206728,"accession_number":"0001104659-24-076578","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Carisma Therapeutics appoints Thorell and Scadden to board; Hodits and Odlander resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Regina Hodits and Björn Odlander resigned from board effective June 30, 2024, citing other professional commitments, not disagreements.","Marella Thorell and David Scadden elected as Class III directors, serving until 2026 annual meeting.","Thorell will chair audit committee; Scadden will chair science committee.","Each new director receives $40k annual cash retainer and option for 38,700 shares vesting monthly over 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223945,"accession_number":"0001104659-24-075709","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Carisma nominates first in vivo CAR-M candidate under Moderna collab; $2M milestone triggered","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Development candidate targets Glypican-3 for solid tumors, including hepatocellular carcinoma (HCC).","Nomination triggers a $2M milestone payment to Carisma from Moderna.","Candidate uses Carisma's CAR-M expertise and Moderna's mRNA/LNP platform for in vivo cell therapy.","Moderna leads development and commercialization; four undisclosed oncology targets also nominated.","Pre-clinical data showed successful in vivo creation of CAR-M redirecting myeloid cells against cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223944,"accession_number":"0001104659-24-071796","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Carisma Therapeutics holds annual meeting; all proposals approved by shareholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors John Hohneker, M.D. and Michael Torok elected with 16.7M and 16.0M votes for respectively.","Non-binding advisory say-on-pay proposal approved: 16.7M for, 575K against, 60K abstain.","Ratification of KPMG LLP as independent auditor for FY2024 approved: 24.4M for, 173K against.","Meeting adjourned from June 13 due to technical difficulties; reconvened and completed June 14."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223943,"accession_number":"0001104659-24-071792","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Carisma grants retention options: 125K shares CEO, 85K each CFO/CSO, vesting over 2 years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Steven Kelly receives option for 125,000 shares; CFO Richard Morris and CSO Michael Klichinsky each get 85,000 shares.","Exercise price equals closing price on June 17, 2024 grant date; options vest in two equal installments on first and second anniversaries.","Grants approved by Compensation Committee to incentivize retention during implementation of revised operating plan.","Company intends to make additional retention grants to other employees under the same plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223942,"accession_number":"0001104659-24-059130","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Carisma Therapeutics Q1 net loss $19.0M; cash $56.5M; lead candidate CT-0525 prioritized","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.0M for Q1 2024 vs $24.6M in Q1 2023; R&D expenses $17.5M.","Cash $56.5M as of March 31, 2024; expected to fund operations into Q3 2025.","Pipeline reprioritization: CT-0525 becomes lead; CT-0508 enrollment ceased; CT-1119 paused; workforce reduced ~37%.","Initial CT-0525 Phase 1 data expected by year-end 2024; preclinical fibrosis data presented at ASGCT.","Appointed Eugene Kennedy as CMO; John Hohneker to Board; Chidozie Ugwumba resigned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":3400000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223941,"accession_number":"0001104659-24-045577","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Carisma reports preliminary Phase 1 data for CT-0508; 40.7% target lesion reduction in monotherapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In 14 monotherapy patients, 40.7% of target lesions reduced in size on ≥1 scan across all anatomic sites.","Combination sub-study of CT-0508 with pembrolizumab enrolled 6 patients; data from first 3 shown.","First two combination patients received corticosteroids prior to pembro; both had progressive disease as best response.","Third combination patient achieved stable disease with 46% reduction in one target lesion; PD due to new brain met.","Company notes corticosteroids may reverse CT-0508 activity based on in vitro cell death data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223940,"accession_number":"0001104659-24-041568","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Carisma Therapeutics reports $86.9M net loss; prioritizes CT-0525, cuts workforce 37%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash of $77.6M as of Dec 31, 2023, expected to fund operations into Q3 2025 after restructuring.","R&D expenses were $74.1M in 2023 (up from $56.6M); net loss $86.9M vs $61.2M in 2022.","Prioritizing CT-0525 (anti-HER2 CAR-Monocyte); ceasing new enrollment in CT-0508 study; pausing CT-1119.","Workforce reduction of ~37% in Q2 2024 as part of pipeline reprioritization and cost savings.","Appointed John Hohneker, M.D. to board, effective April 1, 2024; Chidozie Ugwumba resigned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":3400000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260709,"accession_number":"0001104659-23-116005","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Carisma Therapeutics reports Q3 2023 net loss of $21.4M; cash $94.1M funds into Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.4M for Q3 2023 vs. $18.3M for Q3 2022.","Cash, cash equivalents and marketable securities of $94.1M as of Sept 30, 2023.","R&D expenses $19.6M, up $4.0M YoY, driven by CT-0525 preclinical costs.","Selected clinical candidate for CT-1119 (anti-mesothelin CAR-Monocyte); IND targeted for 2025.","Updated Phase 1 data for CT-0508 shows safety and biomarker correlation with stable disease."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":10630000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277996,"accession_number":"0001104659-23-097500","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Carisma Therapeutics Reports Phase 1 CT-0508 Data Showing Safety and Biomarker Correlation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CT-0508 is a HER2-targeted CAR-M therapy for HER2 overexpressing cancers; 14 patients treated across group 1 (n=9) and group 2 (n=5).","Group 1: best overall response of stable disease in 4 of 9 patients; group 2: best overall response was progressive disease.","No dose-limiting toxicities reported; CT-0508 well-tolerated after single-day bolus infusion in group 2.","Translational analyses combining groups show correlation between TME activation, T cell activation, and HER2 status with stable disease.","Company to focus on combination sub-study with pembrolizumab due to T cell exhaustion findings from trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277995,"accession_number":"0001104659-23-089563","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Carisma Q2 net loss $19.9M, cash $117.1M; dosed first patient in CT-0508+KEYTRUDA combo trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Dosed first patient in Phase 1 trial of CT-0508 in combination with KEYTRUDA for HER2-overexpressing solid tumors.","Nominated additional oncology target under Moderna collaboration; total of five nominated targets.","Cash, cash equivalents and marketable securities $117.1M as of June 30, 2023 (down from $139.0M Q1 2023); expected to fund through end of 2024.","Net loss $19.9M for Q2 2023 vs $14.8M for Q2 2022; R&D expenses increased to $18.5M from $14.2M.","Appointed Eric Siegel as General Counsel and Terry Shields as SVP of Human Resources."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":6803000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296037,"accession_number":"0001104659-23-069917","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Carisma shareholders approve tripling authorized common stock to 350M shares and incentive plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 100M to 350M shares (vote: 29.4M for, 1.6M against).","Amendment and restatement of 2014 Stock Incentive Plan approved (vote: 27.1M for, 1.1M against).","Class III directors Regina Hodits and Björn Odlander elected (25.7M and 27.8M votes for, respectively).","Advisory say-on-pay passed (27.9M for, 0.3M against, non-binding).","KPMG ratified as independent auditor for FY2023 (30.9M for, 63k against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296036,"accession_number":"0001104659-23-059849","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Carisma Therapeutics enters up to $100M ATM equity offering through Jefferies, replacing prior $97.8M capacity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["May offer and sell common stock with aggregate offering price up to $100 million via Jefferies as sales agent.","Commission of up to 3% of gross proceeds; Jefferies will use commercially reasonable efforts.","A&R Sale Agreement replaces original 2019 agreement; prospectus supplement filed under effective shelf registration.","Prior remaining capacity of ~$97.8M from earlier prospectus supplements is superseded.","Company may suspend or terminate offering at any time; shares sold at market prices under Rule 415."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296035,"accession_number":"0001104659-23-059817","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Carisma Therapeutics Q1 net loss widens to $24.6M; cash post-merger $139M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.6M in Q1 2023, vs $11.3M in Q1 2022, driven by higher R&D and G&A expenses.","Cash, cash equivalents and marketable securities of $139.0M as of March 31, 2023, vs $52.0M at Dec 31, 2022.","Merger with Sesen Bio closed; net assets acquired $80.3M, concurrent financing raised $30.6M.","Initiated Phase 1 sub-study of CT-0508 + KEYTRUDA; IND for CT-0525 expected H2 2023.","R&D expenses $16.6M (up from $8.8M) and G&A expenses $9.6M (up from $2.2M) vs prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":3243000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296034,"accession_number":"0001104659-23-041238","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K/A","filed_at":"2023-04-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Carisma FY2022 net loss $61.2M, rev $9.8M; merger closed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $61.2M for year ended Dec 31, 2022 (basic EPS $54.65 loss); compared to $40.8M net loss in 2021.","Total revenue of $9.8M from collaboration with Moderna; no revenue in 2021.","Cash, equivalents, marketable securities $52.0M at Dec 31, 2022; plus $105.3M net from merger and pre-closing financing.","Merger with Sesen Bio closed March 7, 2023; combined company renamed Carisma Therapeutics Inc.","Accumulated deficit $158.2M as of Dec 31, 2022; management expects cash runway through end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316561,"accession_number":"0001104659-23-029687","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["1.01","2.01","3.02","3.03","4.01","5.01","5.02","5.03","5.05","7.01","8.01","9.01"],"status":"ready","headline":"Carisma Therapeutics completes reverse merger with Sesen Bio; begins trading as CARM","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed March 7, 2023; Sesen Bio renamed Carisma Therapeutics; ticker changes from SESN to CARM on Nasdaq.","Pre-closing financing of ~$30.6M from Carisma investors purchased 1,964,101 shares; $35M convertible note converted.","Post-merger ~40.25M shares outstanding; exchange ratio allocated ownership between legacy Sesen and Carisma holders.","CVRs issued to pre-merger Sesen stockholders for potential payments from Roche milestone or asset sales.","Auditor changed: Ernst & Young dismissed; KPMG engaged as new independent auditor for FY2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316571,"accession_number":"0001485003-23-000099","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sesen Bio to pay $0.36/share special dividend and issue CVR upon merger close on March 7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special cash dividend of $75M (~$0.36/share) payable by March 10 to holders of record March 7, contingent on merger closing.","Each share receives one Contingent Value Right for potential proceeds from sale of Vicineum/preclinical assets and Roche milestone.","Merger with CARISMA Therapeutics approved by stockholders on March 2, expected to close March 7.","Dividend and CVR issuance contingent on closing of merger with CARISMA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316570,"accession_number":"0001485003-23-000096","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["3.03","5.07","5.03","8.01","9.01"],"status":"ready","headline":"Sesen Bio stockholders approve merger with Carisma; declares $75M special dividend","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Over 88% of votes cast approved the merger with Carisma Therapeutics; merger expected to close March 7, 2023.","Board declared a one-time special cash dividend of $75M ($0.361 per share) payable by March 10, 2023 to record holders on March 7.","Reverse stock split of 1-for-20 approved; effective after trading hours on March 7, 2023; post-split shares trade as CARM on March 8.","Stockholders will receive one Contingent Value Right per share for potential proceeds from Vicineum sale or Roche milestone.","Sesen Bio expects to close merger with approximately $150M cash; $75M returned to stockholders via dividend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316569,"accession_number":"0001485003-23-000089","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sesen Bio reports Q4 net loss $7.6M; reiterates support for Carisma merger ahead of shareholder vote","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $7.6M ($0.04/shr) vs net income $8.9M in Q4 2021; FY net loss $19.9M ($0.10/shr).","Cash, equivalents and marketable securities $166.9M as of Dec 31, 2022.","Board increased special cash dividend to $75M (~$0.36/shr) under amended merger with Carisma; CVR period extended to Mar 2027.","ISS and Glass Lewis recommend voting 'FOR' all merger proposals at Mar 2, 2023 special meeting.","Nasdaq granted exception from $1.00 bid price requirement to complete merger by Mar 10, 2023 or face delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":9800000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316568,"accession_number":"0001485003-23-000068","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sesen Bio gets Nasdaq exception to complete Carisma merger by March 10; delisting risk if not compliant","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Panel granted exception from $1.00 bid price rule to complete merger with Carisma by March 10, 2023.","Special meeting of stockholders on March 2, 2023 to approve merger and reverse stock split.","If compliance not demonstrated by March 10, common stock will be delisted unless further exception granted.","Company must demonstrate compliance with all initial listing requirements upon closing of merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316567,"accession_number":"0001104659-23-020879","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Sesen Bio raises special dividend to $75M, extends CVR through 2027; activist investors back merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Special cash dividend increased to $75M ($0.36/share) from prior ~$70M; up from original $25M.","CVR period for Vicineum proceeds extended from Dec 31, 2023 to March 31, 2027.","Bradley Radoff and Michael Torok (8.7% stake) vote for merger; Torok to join Carisma board.","Special meeting to approve merger set for March 2, 2023; closing expected Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316566,"accession_number":"0001485003-23-000031","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sesen Bio merger partner Carisma appoints Moderna CSO Lin Guey to SAB; merger on track for Q1 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Carisma Therapeutics appointed Lin Guey, PhD (Chief Scientific Officer of Moderna's External Research Ventures) to its Scientific Advisory Board.","Dr. Guey oversees Moderna's partnership with Carisma to develop in vivo engineered CAR-M therapies for cancer.","Merger between Sesen Bio and Carisma expected to close in Q1 2023, subject to stockholder approval and other conditions.","Carisma expects additional preclinical proof-of-concept data for its CAR-M therapy in Q1 2023.","Moderna will fully fund R&D for up to 12 oncology targets under its collaboration with Carisma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316565,"accession_number":"0001104659-23-009939","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sesen Bio discloses ~$0.34/shr special dividend, 25.2% stake in combined company in Carisma merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Expected one-time cash dividend of ~$70M ($0.34/shr) upon merger close; plus CVR up to $0.14/shr from legacy asset sales and Roche milestone.","Sesen Bio stockholders to own 25.2% of combined company valued at $357M, led by Carisma management.","Board conducted 4-month strategic review, contacted 100+ parties, received 42 bids; determined merger maximizes value vs dissolution.","In dissolution scenario, estimated initial distribution only $0.40-$0.60/shr, available after 6+ months, full process up to 3 years.","Special stockholder meeting on March 2, 2023; Sesen Bio urges vote 'FOR'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316564,"accession_number":"0001485003-23-000020","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-02-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Class action securities litigation settlement receives final court approval","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for Southern District of New York granted final approval on January 31, 2023.","Settlement resolves consolidated shareholder class action In re Sesen Bio, Inc. Securities Litigation.","Derivative litigation previously received final approval by Massachusetts court on November 9, 2022.","Settlement terms were previously disclosed in August 2022 Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316563,"accession_number":"0001485003-23-000014","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Carisma appoints prominent oncologist to SAB; merger on track for Q1 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Padmanee Sharma, MD, PhD, from MD Anderson, appointed to Carisma's Scientific Advisory Board.","She brings expertise in immuno-oncology for CAR-M and checkpoint inhibitor combination trials.","Merger with Sesen Bio expected to close in Q1 2023, subject to stockholder approval and conditions.","Phase 1 trial of CT-0508 + Keytruda actively recruiting; first patient anticipated by end of Q1 2023.","Merger agreement amended Dec 29, 2022 to deliver greater value to Sesen Bio stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316562,"accession_number":"0001485003-23-000010","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2023-01-30T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Sesen Bio receives Nasdaq delisting notice; warns of dissolution if merger fails","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Sesen on Jan 25, 2023 of non-compliance with $1.00 bid price; delisting unless hearing requested.","Company plans to request Nasdaq Hearings Panel hearing to stay delisting and remain listed pending decision.","Without pending merger with Carisma, likely path is delisting, SEC deregistration, and court-managed dissolution and liquidation.","In dissolution, only 60%-90% of ~$140M cash (~$0.40-$0.60/share) available for initial distribution, taking 6+ months.","Board unanimously recommends merger vote at Special Meeting on March 2, 2023; seeking reverse stock split approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334829,"accession_number":"0001485003-22-000182","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2022-12-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Sesen Bio Amends Merger with Carisma: Special Dividend Raised to ~$70M, CVR Expanded","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Expected special cash dividend increased from up to $25M to ~$70M ($0.34/share); up from ~$0.12.","Minimum net cash at closing reduced from $100M to $75M; CVR now includes proceeds from Vicineum and other assets.","Merger expected to close Q1 2023; Carisma's ~$30M financing remains committed and concurrent.","Activist Investor Group (Radoff/Torok, 7.4% stake) continues to demand $100M dividend; company offered $70M.","Post-merger Sesen stockholders expected to own 25.2% of combined company under exchange ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334828,"accession_number":"0001485003-22-000167","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2022-12-23T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Sesen Bio terminates license agreement with Qilu Pharma; pays $1.4M termination fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated exclusive license agreement with Qilu Pharmaceutical for Vicineum in Greater China.","One-time aggregate payment of $1,400,000 to Qilu ($1.2M termination fee + $200K contingent).","All rights to Vicineum in China, Hong Kong, Macau, and Taiwan revert to Sesen.","Sesen retains global rights to Vicineum and is exploring strategic alternatives with a financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334827,"accession_number":"0001485003-22-000164","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Carisma updates CT-0508 interim data; merger with Sesen expected to close in 1-2 months","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Updated interim data from CT-0508 Study 101 supports safety profile and tumor infiltration.","Carisma outlines six pre-clinical and clinical milestones expected in 2023.","Merger with Sesen expected to close in 1-2 months, subject to stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334826,"accession_number":"0001485003-22-000158","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sesen Bio obtains final court approval for derivative lawsuit settlement","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for Massachusetts granted final approval on Nov 8, 2022 for settlement of consolidated derivative lawsuits.","Settlement covers In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538, and Tang v. Sesen Bio, Inc., Case No. 2281-cv-00135.","Company also disclosed securities class action settlement hearing set for Jan 23, 2023 in Southern District of New York.","Previously, court granted preliminary approval on Sep 2, 2022; terms in Aug 30, 2022 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334825,"accession_number":"0001485003-22-000154","cik":1485003,"company_name":"Carisma Therapeutics Inc.","ticker":"CARM","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sesen Bio reports Q3 net income $20.5M, announces merger with Carisma Therapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger with Carisma: Sesen stockholders own ~41.7%, Carisma ~58.3% of combined company with ~$180M cash.","Sesen stockholders to receive CVR for potential Roche payments related to EBI-031 asset sale.","Combined company led by Carisma management; focus on CAR-M therapies for cancer.","Q3 revenue $40M from Roche asset sale; net income $20.5M ($0.10 per diluted share).","Cash $184.9M as of Sep 30, 2022; restructuring charges $10.9M from pausing Vicineum development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4185.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-07T23:59:59+00:00|334825"}